Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06281678 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of IBI363 in Subjects with Advanced Solid Malignancies

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 19, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site contacts updated at 1 of 9 sitesv4
  2. Enrollment target: 160 to 178 Study sites: 1 to 9 · Secondary endpoints: details revised at 2 of 2 entriesv3 Show 2 more changesShow less
    • Study sites: 1 to 9
    • Secondary endpoints: details revised at 2 of 2 entries
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 1, 2024 to Apr 8, 2024 · Study site revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 1, 2024 to Apr 8, 2024
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Trial Details
NCT Number NCT06281678
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Enrollment 178 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov